Oral Teriflunomide in relapsing MS study reported

[MSUK]

Genzyme, a Sanofi company , today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif(R)), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS).

The TENERE trial, which included 324 patients, is the second completed study of five efficacy studies of teriflunomide in MS, making the clinical program one of the largest and broadest of any multiple sclerosis agent under development.....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933

[CureOrBust]

Not looking any better than rebif on effectiveness.

No statistical superiority was observed between the Rebif and teriflunomide arms (7mg and 14mg) on risk of treatment failure, the primary composite endpoint of the study. Risk of treatment failure was defined as the occurrence of a confirmed relapse or permanent treatment discontinuation for any cause, whichever came first. In the study, 48.6 percent of patients receiving 7mg of oral teriflunomide (n=109) and 37.8 percent of patients receiving 14 mg of oral teriflunomide (n=111) reached the primary endpoint, versus 42.3 percent of patients receiving interferon beta 1-a (n=104).

But they appear to be taking it to the next step.